Major NHS Trust Expands Breast Cancer Review to 4,500 Cases Amid Systemic Failures

Scope of Crisis Broadens

County Durham and Darlington NHS Foundation Trust has agreed to expand a clinical review of breast cancer cases from 538 examined cases to potentially 4,500 cases stretching back to 2015, up from the original scope beginning in 2023. The expansion follows documented systemic failures including delayed diagnoses, unnecessary surgeries, and at least one patient death. Hospital leadership acknowledged hundreds of patients have already suffered documented harm under current review parameters. The trust's board approved extending the review by one year at a time, with completion estimated to take five years and cost significantly more than the initial £523,000 annual expense.

Pattern of Failures Identified

The review has uncovered recurring clinical themes across breast cancer services, with chief nurse Gill Hunt identifying treatment protocols that deviated from established best practices, excessive surgical interventions, and diagnostic delays as primary concerns. The clinical problems trace their origins to a 2015 service reconfiguration that eliminated breast surgical trainee positions. Multiple external bodies—including the Northern Cancer Alliance, Care Quality Commission, and NHS England—raised concerns over subsequent years that were not adequately addressed. Of the 538 cases reviewed to date, 321 patients experienced some documented form of harm, demonstrating a harm rate exceeding 59 percent.

Leadership Response and Patient Impact

Board chair Alison Marshall delivered a formal apology to affected women and families, stating leadership could not reverse past damage but committed to transparency and honesty moving forward. Patient accounts collected during the BBC's investigation describe profound suffering, with some women reporting feeling devastated by unnecessary surgical procedures. The trust established a dedicated helpline that received approximately 640 patient requests for case reviews, indicating substantial public concern about potential hidden harm. The expanded review will be conducted by nine clinical reviewers examining approximately 80 cases monthly.

Governance and Future Direction

Hunt emphasized that the expanded review would employ a proportionate, evidence-based clinical methodology supported by formal governance oversight and clear clinical rationale for all decisions. She identified important organizational learning around how hospital leadership should respond to concerns raised by patients or external regulatory agencies. The trust framed the extended review as part of its commitment to systemic improvement and accountability, though the five-year timeline underscores the magnitude of ground to be covered.